The FDA’s NDIN pipeline approved a novel ashwagandha-rhodiola blend yesterday, paving the way for a new generation of stress-recovery nutraceuticals. The clinical data showed a 28% reduction in salivary cortisol within 30 days of consistent use.
Industry analysts predict the adaptogen category will reach $4.2B globally by 2027 — driven primarily by consumer demand for non-pharmaceutical stress interventions.
Deixe um comentário